Agata Walczak, MD, PhD; Malgorzata Siger, MD, PhD; Agnieszka Ciach, MD, PhD; et al.
free access
JAMA Neurol. 2013;70(9):1105-1109. doi:10.1001/jamaneurol.2013.3022
Walczak et al assess the safety and efficacy of transdermally applied myelin peptides in patients with relapsing-remitting multiple sclerosis.
Su-Hyun Kim, MD; So-Young Huh, MD; Sun Ju Lee, MS; et al.
free access
JAMA Neurol. 2013;70(9):1110-1117. doi:10.1001/jamaneurol.2013.3071
Kim et al reported the results of rituximab treatment in patients with relapsing neuromyelitis optica or neuromyelitis optica spectrum disorder for a median of 60 months. See the by McKeon and Pittock.
Marcelo Matiello, MD; Janet Schaefer-Klein, BSc; David Sun, PhD; et al.
free access
JAMA Neurol. 2013;70(9):1118-1125. doi:10.1001/jamaneurol.2013.3124
Matiello and colleagues evaluate tissue-specific messenger RNA and protein expression and supramolecular aggregation of aquaporin 4 (AQP4) in mouse, rat, and human tissues in an effort to understand the predilection for optic nerve and spinal cord pathologic changes in neuromyelitis optica (NMO).
Shyam Prabhakaran, MD, MS; Kathleen O鈥橬eill, MHA; Leslie Stein-Spencer, RN; et al.
free access
JAMA Neurol. 2013;70(9):1126-1132. doi:10.1001/jamaneurol.2013.293
Prabhakaran et al evaluate the impact that a citywide policy recommending prehospital triage of patients with suspected stroke to the nearest primary stroke center had on intravenous tissue plasminogen activator (tPA) use in Chicago, Illinois.
Matthew S. Kayser, MD, PhD; Maarten J. Titulaer, MD, PhD; Núria Gresa-Arribas, PhD; et al.
free access
JAMA Neurol. 2013;70(9):1133-1139. doi:10.1001/jamaneurol.2013.3216
Kayser et al determine the frequency, symptoms, and outcome of isolated psychiatric episodes in a cohort of patients with anti鈥N-methyl-d-aspartate (NMDAR) encephalitis.
Thashi Chang, MD, DPhil; Haris Alexopoulos, PhD; Mary McMenamin, DPhil; et al.
free access
JAMA Neurol. 2013;70(9):1140-1147. doi:10.1001/jamaneurol.2013.3499
Chang et al investigate the characteristics and potential pathogenicity of glutamic acid decarboxylase autoantibodies in patients with stiff person syndrome and related disorders.
Joshua M. Shulman, MD, PhD; Kewei Chen, PhD; Brendan T. Keenan, MS; et al.
free access
JAMA Neurol. 2013;70(9):1150-1157. doi:10.1001/jamaneurol.2013.2815
Shulman et al investigate whether Alzheimer disease susceptibility loci from genome-wide association studies affect neuritic plaque pathology and additionally aim to identify novel risk loci for this trait.
Keith A. Vossel, MD, MSc; Alexander J. Beagle, BA; Gil D. Rabinovici, MD; et al.
free access
has audio
JAMA Neurol. 2013;70(9):1158-1166. doi:10.1001/jamaneurol.2013.136
Vossel et al describe common clinical characteristics and treatment outcomes of patients with amnestic mild cognitive impairment or early AD who also have epilepsy or subclinical epileptiform activity.
-
Podcast:
Seizures and Epileptiform Activity in the Early Stages of Alzheimer Disease
Madhav Thambisetty, MD, PhD; E. Jeffrey Metter, MD; An Yang, PhD; et al.
free access
JAMA Neurol. 2013;70(9):1167-1172. doi:10.1001/jamaneurol.2013.284
Thambisetty et al investigate the association between glucose intolerance and insulin resistance and in vivo brain 尾-amyloid burden, measured with carbon 11鈥搇abeled Pittsburgh Compound B and pathological features of Alzheimer disease at autopsy.